Shorter Study Start-Up Times Targeted with Site Assessment Process Tool
Shorter Study Start-Up Times Targeted with Site Assessment Process Tool
Scientific Software Tools (Media, PA) has released the latest version of VISTA, its Web-based automated site technology assessment service. The new service incorporates additional features to assess for e-clinical studies.
VISTA allows qualitative surveys conducted by the investigative site-—including the technology survey—to be completed online, which eliminates paper-based surveys and manual entry into a database. Also, this Web-based process allows investigators a single point of contact for all required surveys.
VISTA presents the data obtained from the surveys and the technical assessment in XML format, which allows for easier data sharing into databases, as well as improved data sharing between different systems used by all parties involved, including clinical staff, investigators, sponsors, and others.
VISTA Plus includes additional data capture and reporting, and VISTA Services includes additional components to the basic service.
Scientific Software Tools, Inc., (610) 891-1640, www.vistasurveys.com
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.